Please see the Editorial Comment by Devaki Shilpa Sudha Surasi discussing this article.
Please see the Author Video associated with this article. BACKGROUND. Early diagnosis is …

Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide.
Patient outcomes are remarkably heterogeneous and the best existing clinical prognostic …

Background Focal therapy aims to treat areas of cancer to confer oncological control whilst
reducing treatment-related functional detriment. Objective To report oncological outcomes …

The field of oncology has witnessed an extraordinary surge in the application of big data and
artificial intelligence (AI). AI development has made multiscale and multimodal data fusion …

Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …

Prostate specific antigen (PSA) is the common biomarker for prostate cancer (PCa).
However, its lack of specificity to differentiate PCa from benign prostate disorders stimulates …

Approaches and techniques used for diagnostic prostate biopsy have undergone
considerable evolution over the past few decades: from the original finger-guided …

Prostate cancer (PCa) diagnosis on multi-parametric magnetic resonance images (MRI)
requires radiologists with a high level of expertise. Misalignments between the MRI …

Purpose: Prostate cancer is predominantly indolent at diagnosis with a small fraction (15%
to 25%) representing aggressive subtype (Gleason score 7-10), which is prone to metastatic …

Prostate cancer (PC) is one of the most common cancers in males and the fifth leading
reason of death. Age, ethnicity, family history, and genetic defects are major factors that …